Intellia Therapeutics Inc Asset Turnover Ratio (NTLA), as of second quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket
 


Intellia Therapeutics Inc   (NASDAQ: NTLA)
 

Intellia Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Due to the increase in investments during the second quarter 2026, Intellia Therapeutics Inc 's asset turnover ratio sequentially decreased to 0.07 in the second quarter (Jun 30 2026), this is lower than usual.

Within sector 7 more businesses have achieved higher asset turnover ratio. While Asset turnover ratio total ranking has improved so far during the II Quarter 2026, to 1881, from total ranking in the first quarter 2026 at 2610.

Asset Turnover Ratio Definition



NTLA Asset Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Asset Change -4.64 % -23.06 % -13.5 % -13.96 % -17.33 %
Y / Y Revenue Change -46.23 % -9.5 % 78.79 % 51.27 % 104.76 %
Asset Turnover Ratio (TTM) 0.07 0.08 0.07 0.06 0.05
NTLA's Total Ranking # 1881 # 2610 # 2221 # 3054 #
Seq. Asset Change 12.97 % -9.9 % -8.99 % 2.93 % -8.85 %
Seq. Revenue Change -49.1 % -34.62 % 67.01 % -3.25 % -14.33 %



Asset Turnover Ratio Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 247
Overall Market # 1881

Asset Turnover Ratio Statistics
High Average Low
26.58 10.59 3.5
(Jun 30 2021)   (Dec 31 2024)







Companies with similar Asset Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Assets at quarter ending Jun 30 2026
Moderna Inc   0.19 $ 2,228.000  Millions$ 11,730.500  Millions
4d Molecular Therapeutics Inc   0.18 $ 92.008  Millions$ 499.053  Millions
Nrx Pharmaceuticals Inc   0.18 $ 3.394  Millions$ 18.504  Millions
Bioadaptives Inc   0.18 $ 0.026  Millions$ 0.141  Millions
Renovorx Inc   0.18 $ 1.976  Millions$ 11.184  Millions
Coya Therapeutics Inc   0.18 $ 8.019  Millions$ 45.643  Millions
Ligand Pharmaceuticals Incorporated  0.17 $ 290.542  Millions$ 1,688.847  Millions
Septerna Inc   0.17 $ 98.882  Millions$ 584.816  Millions
Inspiremd Inc   0.17 $ 10.502  Millions$ 62.247  Millions
Prelude Therapeutics Inc  0.16 $ 22.424  Millions$ 136.269  Millions
Opus Genetics Inc   0.16 $ 9.856  Millions$ 61.530  Millions
Skinvisible Inc   0.16 $ 0.020  Millions$ 0.126  Millions
Maxcyte inc   0.16 $ 31.051  Millions$ 198.782  Millions
Abeona Therapeutics Inc   0.15 $ 30.093  Millions$ 207.166  Millions
Voyager Therapeutics Inc   0.14 $ 34.459  Millions$ 239.417  Millions
Standard Biotools Inc   0.14 $ 83.691  Millions$ 593.430  Millions
Femasys Inc   0.14 $ 2.299  Millions$ 16.450  Millions
Seastar Medical Holding Corp  0.14 $ 1.713  Millions$ 12.400  Millions
Sintx Technologies Inc   0.14 $ 1.330  Millions$ 9.778  Millions
Lucid Diagnostics Inc   0.13 $ 5.445  Millions$ 41.667  Millions
Omniab Inc   0.13 $ 38.457  Millions$ 298.628  Millions
Lineage Cell Therapeutics Inc   0.13 $ 13.083  Millions$ 104.494  Millions
Igc Pharma Inc   0.12 $ 1.101  Millions$ 9.293  Millions
Kura Oncology Inc   0.12 $ 77.225  Millions$ 657.022  Millions
Arcturus Therapeutics Holdings Inc   0.11 $ 29.368  Millions$ 255.803  Millions
China Pharma Holdings Inc  0.11 $ 3.914  Millions$ 34.164  Millions
Pmgc Holdings Inc   0.11 $ 2.579  Millions$ 22.601  Millions
Tonix Pharmaceuticals Holding Corp   0.11 $ 29.102  Millions$ 260.403  Millions
Beam Therapeutics Inc   0.11 $ 156.035  Millions$ 1,414.853  Millions
Surrozen Inc   0.11 $ 11.511  Millions$ 107.272  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.